Positive PD-L1 Expression Is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with EGFR-TKIs

被引：0
|
作者：
Lee, S. H. [1 ]
Park, M. J. [1 ]
Chang, B. [1 ]
机构：
[1] Kyung Hee Univ, Med Ctr, Dept Internal Med, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
EGFR-TKIs; programmed death ligand; Clinical outcome;
D O I：
10.1016/j.jtho.2019.08.1195
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.14-44
引用
收藏
页码：S572 / S572
页数：1
相关论文
共 50 条
  • [41] High Tumor Mutation Burden Predicts Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinoma Treated With Targeted Therapy
    Lee, S. H.
    Sung, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S932 - S932
  • [42] Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
    Chu, Chang-Yao
    Lin, Chien-Yu
    Lin, Chien-Chung
    Li, Chien-Feng
    Wu, Shang-Yin
    Tsai, Jeng-Shiuan
    Yang, Szu-Chun
    Chen, Chian-Wei
    Lin, Chia-Yin
    Chang, Chao-Chun
    Yen, Yi-Ting
    Tseng, Yau-Lin
    Su, Po-Lan
    Su, Wu-Chou
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [43] Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
    Chang-Yao Chu
    Chien-Yu Lin
    Chien-Chung Lin
    Chien-Feng Li
    Shang-Yin Wu
    Jeng-Shiuan Tsai
    Szu-Chun Yang
    Chian-Wei Chen
    Chia-Yin Lin
    Chao-Chun Chang
    Yi-Ting Yen
    Yau-Lin Tseng
    Po-Lan Su
    Wu-Chou Su
    Scientific Reports, 13
  • [44] Combination of Radiotherapy and PD-L1 Blockade Induces Abscopal Responses in EGFR-mutated Lung Cancer
    Xia, W.
    Fu, X. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S431 - S431
  • [45] Monitoring the response of PD-L1 expression to EGFR-TKIs in NSCLC xenografts by immuno-PET imaging
    Li, Dan
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S435 - S435
  • [46] Efficacy of Immune-Checkpoint Inhibitors and EGFR-TKIs in NSCLC Patients with High PD-L1 Expression
    Masuda, K.
    Horinouchi, H.
    Tanaka, M.
    Higashiyama, R.
    Shinno, Y.
    Sato, J.
    Yoshida, T.
    Matsumoto, Y.
    Goto, Y.
    Kanda, S.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S292 - S293
  • [47] PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway
    Li, Na
    Zuo, Ran
    He, Yuchao
    Gong, Wenchen
    Wang, Yu
    Chen, Liwei
    Luo, Yi
    Zhang, Cuicui
    Liu, Zhiyong
    Chen, Peng
    Guo, Hua
    CELL DEATH & DISEASE, 2024, 15 (08):
  • [48] Genomic Characteristics and Clonal Evolution of EGFR-mutated Lung Adenocarcinoma-Transformed Squamous Carcinoma after EGFR-TKIs Treatment
    Kang, J.
    Yang, X. -N.
    Yan, L. -X.
    Yan, L.
    Yang, J. -J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S335 - S335
  • [49] Nivolumab plus chemotherapy vs chemotherapy in EGFR-mutated NSCLC after 1L or 2L EGFR-TKIs (CheckMate 722)
    Park, Keunchil
    Yang, James Chih-Hsin
    Girard, Nicolas
    Mok, Tony
    Gainor, Justin
    Nakagawa, Kazuhiko
    Wu, Yi-Long
    Xu, Wanning
    Yang, Rong
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer
    Shiozawa, Toshihiro
    Numata, Takeshi
    Tamura, Tomohiro
    Endo, Takeo
    Kaburagi, Takayuki
    Yamamoto, Yusuke
    Yamada, Hideyasu
    Kikuchi, Norihiro
    Saito, Kazuhito
    Inagaki, Masaharu
    Kurishima, Koichi
    Funayama, Yasunori
    Miyazaki, Kunihiko
    Koyama, Nobuyuki
    Furukawa, Kinya
    Nakamura, Hiroyuki
    Kikuchi, Shinji
    Ichimura, Hideo
    Sato, Yukio
    Sekine, Ikuo
    Satoh, Hiroaki
    Hizawa, Nobuyuki
    ANTICANCER RESEARCH, 2022, 42 (05) : 2583 - 2590
12345